Cyprium Therapeutics focuses on the development of novel therapies treatment for Menkes disease and related copper metabolism disorders.
Cyprium Therapeutics has raised $4.1M in total funding. The most recent round was Grant. The last funding was announced in March 2024.
Cyprium Therapeutics's investors include National Institute of Neurological Disorders and Stroke.
Cyprium Therapeutics is headquartered in New York, United States.
Cyprium Therapeutics focuses on the development of novel therapies treatment for Menkes disease and related copper metabolism disorders.
Cyprium Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cyprium Therapeutics — Funding & Investors." VCBacked, March 4, 2024, https://www.vcbacked.co/company/cyprium-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). Cyprium Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cyprium-therapeutics
{{cite web |title=Cyprium Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cyprium-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated